Cargando…

Natural disease history of the dy(2J) mouse model of laminin α2 (merosin)-deficient congenital muscular dystrophy

Merosin deficient congenital muscular dystrophy 1A (MDC1A) is a very rare autosomal recessive disorder caused by mutations in the LAMA2 gene leading to severe and progressive muscle weakness and atrophy. Although over 350 causative mutations have been identified for MDC1A, no treatment is yet availa...

Descripción completa

Detalles Bibliográficos
Autores principales: Pasteuning-Vuhman, S., Putker, K., Tanganyika-de Winter, C. L., Boertje-van der Meulen, J. W., van Vliet, L., Overzier, M., Plomp, J. J., Aartsma-Rus, A., van Putten, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5953480/
https://www.ncbi.nlm.nih.gov/pubmed/29763467
http://dx.doi.org/10.1371/journal.pone.0197388
_version_ 1783323363695919104
author Pasteuning-Vuhman, S.
Putker, K.
Tanganyika-de Winter, C. L.
Boertje-van der Meulen, J. W.
van Vliet, L.
Overzier, M.
Plomp, J. J.
Aartsma-Rus, A.
van Putten, M.
author_facet Pasteuning-Vuhman, S.
Putker, K.
Tanganyika-de Winter, C. L.
Boertje-van der Meulen, J. W.
van Vliet, L.
Overzier, M.
Plomp, J. J.
Aartsma-Rus, A.
van Putten, M.
author_sort Pasteuning-Vuhman, S.
collection PubMed
description Merosin deficient congenital muscular dystrophy 1A (MDC1A) is a very rare autosomal recessive disorder caused by mutations in the LAMA2 gene leading to severe and progressive muscle weakness and atrophy. Although over 350 causative mutations have been identified for MDC1A, no treatment is yet available. There are many therapeutic approaches in development, but the lack of natural history data of the mouse model and standardized outcome measures makes it difficult to transit these pre-clinical findings to clinical trials. Therefore, in the present study, we collected natural history data and assessed pre-clinical outcome measures for the dy(2J)/dy(2J) mouse model using standardized operating procedures available from the TREAT-NMD Alliance. Wild type and dy(2J)/dy(2J) mice were subjected to five different functional tests from the age of four to 32 weeks. Non-tested control groups were taken along to assess whether the functional test regime interfered with muscle pathology. Respiratory function, body weights and creatine kinase levels were recorded. Lastly, skeletal muscles were collected for further histopathological and gene expression analyses. Muscle function of dy(2J)/dy(2J) mice was severely impaired at four weeks of age and all mice lost the ability to use their hind limbs. Moreover, respiratory function was altered in dy(2J)/dy(2J) mice. Interestingly, the respiration rate was decreased and declined with age, whereas the respiration amplitude was increased in dy(2J)/dy(2J) mice when compared to wild type mice. Creatine kinase levels were comparable to wild type mice. Muscle histopathology and gene expression analysis revealed that there was a specific regional distribution pattern of muscle damage in dy(2J)/dy(2J) mice. Gastrocnemius appeared to be the most severely affected muscle with a high proportion of atrophic fibers, increased fibrosis and inflammation. By contrast, triceps was affected moderately and diaphragm only mildly. Our study presents a complete natural history dataset which can be used in setting up standardized studies in dy(2J)/dy(2J) mice.
format Online
Article
Text
id pubmed-5953480
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-59534802018-05-25 Natural disease history of the dy(2J) mouse model of laminin α2 (merosin)-deficient congenital muscular dystrophy Pasteuning-Vuhman, S. Putker, K. Tanganyika-de Winter, C. L. Boertje-van der Meulen, J. W. van Vliet, L. Overzier, M. Plomp, J. J. Aartsma-Rus, A. van Putten, M. PLoS One Research Article Merosin deficient congenital muscular dystrophy 1A (MDC1A) is a very rare autosomal recessive disorder caused by mutations in the LAMA2 gene leading to severe and progressive muscle weakness and atrophy. Although over 350 causative mutations have been identified for MDC1A, no treatment is yet available. There are many therapeutic approaches in development, but the lack of natural history data of the mouse model and standardized outcome measures makes it difficult to transit these pre-clinical findings to clinical trials. Therefore, in the present study, we collected natural history data and assessed pre-clinical outcome measures for the dy(2J)/dy(2J) mouse model using standardized operating procedures available from the TREAT-NMD Alliance. Wild type and dy(2J)/dy(2J) mice were subjected to five different functional tests from the age of four to 32 weeks. Non-tested control groups were taken along to assess whether the functional test regime interfered with muscle pathology. Respiratory function, body weights and creatine kinase levels were recorded. Lastly, skeletal muscles were collected for further histopathological and gene expression analyses. Muscle function of dy(2J)/dy(2J) mice was severely impaired at four weeks of age and all mice lost the ability to use their hind limbs. Moreover, respiratory function was altered in dy(2J)/dy(2J) mice. Interestingly, the respiration rate was decreased and declined with age, whereas the respiration amplitude was increased in dy(2J)/dy(2J) mice when compared to wild type mice. Creatine kinase levels were comparable to wild type mice. Muscle histopathology and gene expression analysis revealed that there was a specific regional distribution pattern of muscle damage in dy(2J)/dy(2J) mice. Gastrocnemius appeared to be the most severely affected muscle with a high proportion of atrophic fibers, increased fibrosis and inflammation. By contrast, triceps was affected moderately and diaphragm only mildly. Our study presents a complete natural history dataset which can be used in setting up standardized studies in dy(2J)/dy(2J) mice. Public Library of Science 2018-05-15 /pmc/articles/PMC5953480/ /pubmed/29763467 http://dx.doi.org/10.1371/journal.pone.0197388 Text en © 2018 Pasteuning-Vuhman et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Pasteuning-Vuhman, S.
Putker, K.
Tanganyika-de Winter, C. L.
Boertje-van der Meulen, J. W.
van Vliet, L.
Overzier, M.
Plomp, J. J.
Aartsma-Rus, A.
van Putten, M.
Natural disease history of the dy(2J) mouse model of laminin α2 (merosin)-deficient congenital muscular dystrophy
title Natural disease history of the dy(2J) mouse model of laminin α2 (merosin)-deficient congenital muscular dystrophy
title_full Natural disease history of the dy(2J) mouse model of laminin α2 (merosin)-deficient congenital muscular dystrophy
title_fullStr Natural disease history of the dy(2J) mouse model of laminin α2 (merosin)-deficient congenital muscular dystrophy
title_full_unstemmed Natural disease history of the dy(2J) mouse model of laminin α2 (merosin)-deficient congenital muscular dystrophy
title_short Natural disease history of the dy(2J) mouse model of laminin α2 (merosin)-deficient congenital muscular dystrophy
title_sort natural disease history of the dy(2j) mouse model of laminin α2 (merosin)-deficient congenital muscular dystrophy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5953480/
https://www.ncbi.nlm.nih.gov/pubmed/29763467
http://dx.doi.org/10.1371/journal.pone.0197388
work_keys_str_mv AT pasteuningvuhmans naturaldiseasehistoryofthedy2jmousemodeloflaminina2merosindeficientcongenitalmusculardystrophy
AT putkerk naturaldiseasehistoryofthedy2jmousemodeloflaminina2merosindeficientcongenitalmusculardystrophy
AT tanganyikadewintercl naturaldiseasehistoryofthedy2jmousemodeloflaminina2merosindeficientcongenitalmusculardystrophy
AT boertjevandermeulenjw naturaldiseasehistoryofthedy2jmousemodeloflaminina2merosindeficientcongenitalmusculardystrophy
AT vanvlietl naturaldiseasehistoryofthedy2jmousemodeloflaminina2merosindeficientcongenitalmusculardystrophy
AT overzierm naturaldiseasehistoryofthedy2jmousemodeloflaminina2merosindeficientcongenitalmusculardystrophy
AT plompjj naturaldiseasehistoryofthedy2jmousemodeloflaminina2merosindeficientcongenitalmusculardystrophy
AT aartsmarusa naturaldiseasehistoryofthedy2jmousemodeloflaminina2merosindeficientcongenitalmusculardystrophy
AT vanputtenm naturaldiseasehistoryofthedy2jmousemodeloflaminina2merosindeficientcongenitalmusculardystrophy